Abstract:Background: Long QT syndrome 3 (LQT3) is caused by SCN5A mutations. Late sodium current (late INa) inhibitors are current-specific to treat patients with LQT3, but the mechanisms underlying mexiletine (MEX) -sensitive (N1325S and R1623Q) and -insensitive (M1652R) mutations remains to be elucidated.Methods: LQT3 patients with causative mutations were treated with oral MEX following i.v. lidocaine. Whole-cell patch-clamp techniques and molecular remodeling were used to determine the mechanisms underlying the sensitivity to MEX.Results: Intravenous administration of lidocaine followed by MEX orally in LQT patients with N1325S and R1623Q sodium channel mutation shortened QTc interval, abolished arrhythmias, and completely normalized the ECG. In HEK293 cells, the steady-state inactivation curves of the M1652R channels were rightward shifted by 5.6 mV relative to the WT channel. In contrast, the R1623Q mutation caused a leftward shift of the steady-state inactivation curve by 15.2 mV compared with WT channel, and N1325S mutation did not affect steady-state inactivation (n = 5–13, P < 0.05). The extent of the window current was expanded in all three mutant channels compared with WT. All three mutations increased late INa with the greatest amplitude in the M1652R channel (n = 9–15, P < 0.05). MEX caused a hyperpolarizing shift of the steady-state inactivation and delayed the recovery of all three mutant channels. Furthermore, it suppressed late INa in N1325S and R1623Q to a greater extent compared to that of M1652R mutant channel. Mutations altered the sensitivity of Nav1.5 to MEX through allosteric mechanisms by changing the conformation of Nav1.5 to become more or less favorable for MEX binding. Late INa inhibitors suppressed late INa in N1325S and R1623Q to a greater extent than that in the M1652R mutation (n = 4–7, P < 0.05).Conclusion: The N1325S, R1623Q, and M1652R mutations are associated with a variable augmentation of late INa, which was reversed by MEX. M1652R mutation changes the conformation of Nav1.5 that disrupt the inactivation of channel affecting MEX binding, corresponding to the poor response to MEX. The lidocaine test, molecular modeling, and drugs screening in cells expressing mutant channels are useful for predicting the effectiveness of late INa inhibitors.

Abstract P2096: Long Qt Syndrome Type 3 Phenotype Dependence On Extracellular Sodium And The Perinexus In A Genetic Mouse Model

Transmural Gradient of Ito and INak Profoundly Influence Ventricular Action Potential Duration

Altered Sinoatrial Node Function and Intra-Atrial Conduction in Murine Gain-of-function Scn5a+/ΔKPQ Hearts Suggest an Overlap Syndrome

Atrial Arrhythmogenesis in Wild-Type and Scn5a+/Δ Murine Hearts Modelling LQT3 Syndrome

Mechanisms by Which SCN5A Mutation N1325S Causes Cardiac Arrhythmias and Sudden Death in Vivo.

Effects of Pharmacological Gap Junction and Sodium Channel Blockade on S1S2 Restitution Properties in Langendorff-perfused Mouse Hearts

Electrophysiologic effects of nicorandil on the guinea pig long QT1 syndrome model.

Abstract 14727: Late Sodium Current Plays a Role in Ventricular Arrhythmias Associated with Increased Intracellular Calcium Concentration

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3

Development of a Patient-Specific P.d85n-Potassium Voltage-Gated Channel Subfamily E Member 1–induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for Drug-Induced Long QT Syndrome

A Molecular Mechanism for Adrenergic-Induced Long QT Syndrome.

Effects of amiodarone on rodent ventricular cardiomyocytes: Novel perspectives from a cellular model of Long QT Syndrome Type 3

Modelling the Effects of Quinidine, Disopyramide, and E-4031 on Short QT Syndrome Variant 3 in the Human Ventricles

Contribution of Late Sodium Current (Ina-L) to Rate Adaptation of Ventricular Repolarization and Reverse Use-Dependence of Qt-Prolonging Agents

Characterization of the cardiac sodium channel SCN5A mutation, N1325S, in single murine ventricular myocytes

SGK1 inhibition normalizes action potential duration in transgenic LQT2 rabbits but not in LQT1, suggesting a novel gene-specific therapeutic approach in long QT syndrome

Nonlinear Analysis of Beat-To-Beat Variability of Action Potential Time Series Data Identifies Dynamic Reentrant Substrates in a Hypokalaemic Mouse Model of Acquired Long QT Syndrome

Defining Cardiomyocyte Repolarization Response to Pharmacotherapy in Long-QT Syndrome Type 3

Abstract 15660: Propranolol Inhibits Late Sodium Current in Long-QT Syndrome Type 3 Human Induced Pluripotent Stem Cell-drived Myocyte Model

The Electrophysiologic Effects of Β-Adrenergic Agonists on LQT1 Models of the Long QT Syndrome

Pathophysiological Mechanisms of Sino-Atrial Dysfunction and Ventricular Conduction Disease Associated with SCN5A Deficiency: Insights from Mouse Models